

Horizon Pharma plc  
Form 8-K  
September 20, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 17, 2018**

**Horizon Pharma Public Limited Company**

**(Exact name of registrant as specified in its charter)**

**Ireland**  
**(State or other jurisdiction**  
**of incorporation)**

**001-35238**  
**(Commission**

**Not Applicable**  
**(IRS Employer**

**File No.)**

**Identification No.)**

**Connaught House, 1<sup>st</sup> Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland**

(Address of principal executive offices)

Registrant's telephone number, including area code: 011-353-1-772-2100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01 Entry into a Material Definitive Agreement.**

On September 17, 2018, a subsidiary of Horizon Pharma plc (the Horizon Subsidiary) entered into a Settlement and License Agreement (the Settlement Agreement) with Par Pharmaceutical, Inc. (Par) relating to RAVICTI (Racemic cerol phenylbutyrate) Oral Liquid, 1.1 gm/mL. Specifically, the Settlement Agreement pertains to on-going patent infringement litigation against Par in the U.S. District Court for the District of New Jersey and the District of Delaware (the Litigation) and petitions for *inter partes* review with the Patent Trial and Appeal Board with respect to certain U.S. patents covering RAVICTI (the IPRs). In the Litigation, the Horizon Subsidiary has alleged that a generic version of RAVICTI, for which Par is seeking approval to market in the United States pursuant to an Abbreviated New Drug Application (ANDA), infringes certain U.S. patents that are owned by the Horizon Subsidiary.

The parties have agreed to file stipulations of dismissal with the courts regarding the Litigation and a joint request for termination in the IPRs. The Settlement Agreement also provides for a full settlement and release by each party of all claims that relate to Par's generic version of RAVICTI or the Litigation or the IPRs.

Under the Settlement Agreement, the Horizon Subsidiary granted Par a non-exclusive, perpetual, royalty-free license to manufacture and commercialize Par's generic version of RAVICTI in the United States after the License Effective Date (as defined below) and to take steps necessary to develop inventory of, and prepare to commercialize, Par's generic version of RAVICTI during certain limited periods prior to the License Effective Date.

Under the Settlement Agreement, the License Effective Date is July 1, 2025; however, Par may be able to enter the market earlier in certain circumstances.

The Horizon Subsidiary also agreed not to sue or assert any claim against Par for infringement of any patent or patent application owned or controlled by the Horizon Subsidiary during the term of the Settlement Agreement based on the manufacture, use, sale, offer for sale, or importation of Par's generic version of RAVICTI in the United States. In turn, Par agreed not to challenge the validity or enforceability of the licensed patents.

The foregoing description of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the agreement, which will be filed, with confidential terms redacted, with the U.S. Securities and Exchange Commission as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2018.

Par was the first entity to file an ANDA with respect to RAVICTI. As previously disclosed, the Horizon Subsidiary entered into a Settlement and License Agreement with Lupin Ltd. and Lupin Pharmaceuticals, Inc., the other entities to file an ANDA with respect to RAVICTI, on June 27, 2018.

**Forward-Looking Statements**

This report contains forward-looking statements, including statements regarding the anticipated results and actions to be taken under the Settlement Agreement. These forward-looking statements are based on management's expectations and assumptions as of the date of this report and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include, but are not limited to risks regarding whether regulatory authorities challenge the enforceability of or seek to enjoin the entry into the Settlement Agreement, whether the courts will grant orders dismissing the Litigation, whether the IPRs will be terminated following the parties' joint request for termination, whether additional third parties may seek to market generic versions of RAVICTI and the results of any litigation that Horizon Pharma plc files to defend and/or assert its patents against such third parties. For a further description of these and other risks facing Horizon Pharma plc, please see the risk factors described in Horizon Pharma plc's filings with the U.S. Securities and Exchange Commission, including those factors discussed under the caption Risk Factors in those filings. Forward-looking statements speak only as of the date of this report and Horizon Pharma plc undertakes no obligation to update or revise these statements, except as

may be required by law.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 20, 2018

**HORIZON PHARMA PUBLIC LIMITED  
COMPANY**

By: /s/ Paul W. Hoelscher  
Paul W. Hoelscher  
Executive Vice President, Chief Financial Officer